Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
This is a randomized investigator and participant blinded, sponsor unblinded, multicenter study that evaluates the safety and efficacy of ociperlimab with tislelizumab and histology-based chemotherapy compared with treatment with tislelizumab and histology-based chemotherapy in participants with previously untreated locally advanced, unresectable, or metastatic NSCLC
Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)|Nonsmall Cell Lung Cancer, Stage IV
DRUG: Ociperlimab|DRUG: Tislelizumab|DRUG: histology-based chemotherapy|DRUG: Placebo
Progression-free Survival (PFS) as Assessed by Investigators, PFS will be defined as the time from the date of randomization to the date of the first objectively documented tumor progression per RECIST v1.1, or death, whichever occurs first, Up to approximately 30 months
Overall Response Rate (ORR) as Assessed by Investigators, ORR will be defined as the proportion of participants with a documented, confirmed complete response or partial response per RECIST v1.1., Up to approximately 30 months|Duration of Response (DoR) As Assessed by Investigators, DOR is defined as the time from the first determination of an objective response (OR) per RECIST v1.1 until the first documentation of progression., Up to approximately 30 months|Overall Survival (OS), OS will be defined as the time from the date of randomization to the date of death due to any cause., Up to approximately 30 months|Number of Participants Experiencing Adverse Events (AEs), The incidence and severity of AEs will be determined according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)., 90 days (Â±14) after last dose
This is a randomized investigator and participant blinded, sponsor unblinded, multicenter study that evaluates the safety and efficacy of ociperlimab with tislelizumab and histology-based chemotherapy compared with treatment with tislelizumab and histology-based chemotherapy in participants with previously untreated locally advanced, unresectable, or metastatic NSCLC